Trials / Completed
CompletedNCT00585078
Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Beth Israel Deaconess Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
There are limited treatment options available for patients with advanced pancreatic ductal adenocarcinoma (PDAC). The purpose of this study is to determine the effectiveness and safety of the drugs capecitabine and oxaliplatin in patients who have been diagnosed with advanced and metastatic PDAC treated in the first and second lines.
Detailed description
OBJECTIVES: Primary * To determine the response rate to capecitabine and oxaliplatin in patients with locally advanced or metastatic pancreatic adenocarcinoma Secondary * To determine safety * To determine overall survival * To determine time to progression
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | |
| DRUG | Oxaliplatin |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2008-01-03
- Last updated
- 2017-04-10
- Results posted
- 2017-04-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00585078. Inclusion in this directory is not an endorsement.